Raymond James & Associates, Inc. acted as financial advisor to Orrstown and delivered a fairness opinion to the Board of Directors of Orrstown. Goodwin Procter LLP...
Orrstown Financial Services’ Merger with Codorus Valley Bancorp
Pathos AI’s Acquisition of Rain Oncology
Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
York Capital Management’s Partnership with Comprehensive Rehab Consultants
Goodwin Procter advised York Capital Management in its strategic growth investment in Comprehensive Rehab Consultants. William Blair acted as the sell-side investment banking advisor to CRC....
Kyowa Kirin’s $387 Million Acquisition of Orchard Therapeutics
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Eli Lilly’s $1.925 Billion Acquisition of Versanis Bio
Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
Coherus’ Acquisition of Surface Oncology
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
Quest Diagnostics’ Acquisition of Haystack Oncology
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
JMI Equity’s $90 Million Investment in Coursedog
Goodwin Procter advised JMI Equity on the deal. JMI Equity announced its $90 million strategic growth investment in Coursedog. JMI Equity is a growth equity firm focused...
TCR² Therapeutics’ Agreement with Adaptimmune Therapeutics
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
Onex’s Investment in Unanet
Goodwin Procter advised Unanet and JMI Equity on the deal, while Latham & Watkins represented Onex. Unanet announced a new round of strategic financing from Onex Corporation...